Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

Cel

Chronic inflammatory diseases and their comorbidities pose a major global health burden, with conditions such as rheumatoid arthritis (RA) and associated cardiovascular disease (CVD) affecting hundreds of millions worldwide. Current anti-inflammatory therapies alleviate symptoms but rarely restore tissue homeostasis, leaving patients at risk of persistent inflammation and long-term damage.

Addressing this challenge requires researchers trained not only in classical immunology and pharmacology but also in the emerging field of Resolution Pharmacology, which aims to activate endogenous pathways that terminate inflammation and promote tissue repair. Yet the interdisciplinary expertise required, spanning resolution biology, GPCR signalling, advanced multi-omics, systems analysis, and translational development, is not available within existing programmes, creating a critical skills gap that limits progress.

HARPNET addresses this unmet need through an innovation-driven training programme uniting 14 beneficiaries and 11 associated partners. Fifteen Doctoral Candidates (DCs) will be embedded in cross-disciplinary teams that co-develop cutting-edge methodologies, including integrated multi-omic pipelines, systems-level disease models, and next-generation approaches to target pro-resolving pathways. This will equip DCs with the scientific, technical, and translational competencies required to drive mechanism-based therapeutic innovation.

Using RA and RA-associated CVD as clinically relevant models, HARPNET will deliver hands-on, systems-level, cross-sectoral training across academic, clinical, and industrial settings. Through this comprehensive and co-creative programme, DCs will bridge discovery research with therapeutic development, generating transferable tools and knowledge that extend beyond the network. HARPNET will strengthen Europe’s long-term capacity to lead in Resolution Pharmacology and to train the next generation of innovators in inflammation research.

Dziedzina nauki (EuroSciVoc)

Projekt nie został jeszcze sklasyfikowany według klasyfikacji EuroSciVoc.
Wskaż dziedziny nauki, które twoim zdaniem są najbardziej istotne z punktu widzenia tego projektu i pomóż nam usprawnić naszą usługę klasyfikacji.

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) HORIZON-MSCA-2025-DN-01

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

QUEEN MARY UNIVERSITY OF LONDON
Wkład UE netto
€ 1 394 952,48
Koszt całkowity
Brak danych

Uczestnicy (11)

Partnerzy (13)